DE19962924A1
(de)
|
1999-12-24 |
2001-07-05 |
Bayer Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
US6710058B2
(en)
|
2000-11-06 |
2004-03-23 |
Bristol-Myers Squibb Pharma Company |
Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
|
DE10105989A1
(de)
*
|
2001-02-09 |
2002-08-14 |
Bayer Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE10129725A1
(de)
*
|
2001-06-20 |
2003-01-02 |
Bayer Ag |
Kombinationstherapie substituierter Oxazolidinone
|
CA2464109A1
(en)
*
|
2001-10-18 |
2003-12-24 |
Michigan State University |
Process for the preparation of oxazolidinones and method of use thereof
|
DE10152460A1
(de)
*
|
2001-10-24 |
2003-05-08 |
Bayer Ag |
Stents
|
US7022705B2
(en)
|
2001-10-25 |
2006-04-04 |
Astrazeneca Ab |
Isoxazoline derivatives useful as antimicrobials
|
CA2477604A1
(en)
|
2002-03-13 |
2003-09-25 |
Signum Biosciences, Inc. |
Modulation of protein methylation and phosphoprotein phosphate
|
DE10300111A1
(de)
|
2003-01-07 |
2004-07-15 |
Bayer Healthcare Ag |
Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
|
US7012088B2
(en)
|
2003-02-24 |
2006-03-14 |
Pharmacia & Upjohn Company |
Indolone oxazolidinones and derivatives thereof
|
DE10322469A1
(de)
*
|
2003-05-19 |
2004-12-16 |
Bayer Healthcare Ag |
Heterocyclische Verbindungen
|
DE10336716A1
(de)
*
|
2003-08-11 |
2005-03-10 |
Merck Patent Gmbh |
Verfahren zur Herstellung von N-Aryl-morpholinonen
|
DE10342570A1
(de)
*
|
2003-09-15 |
2005-04-14 |
Bayer Healthcare Ag |
Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
|
DE10355461A1
(de)
*
|
2003-11-27 |
2005-06-23 |
Bayer Healthcare Ag |
Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
|
DE102004002044A1
(de)
*
|
2004-01-15 |
2005-08-04 |
Bayer Healthcare Ag |
Herstellverfahren
|
US7371743B2
(en)
*
|
2004-02-28 |
2008-05-13 |
Boehringer Ingelheim International Gmbh |
Carboxylic acid amides, the preparation thereof and their use as medicaments
|
EP1571154A1
(en)
*
|
2004-03-03 |
2005-09-07 |
Aventis Pharma Deutschland GmbH |
Beta-aminoacid-derivatives as factor Xa inhibitors
|
US7550499B2
(en)
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
WO2005111013A1
(de)
*
|
2004-05-13 |
2005-11-24 |
Boehringer Ingelheim International Gmbh |
Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
|
JP2007537180A
(ja)
|
2004-05-13 |
2007-12-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規置換チオフェンカルボキサミド、それらの調製方法及び薬物としてのそれらの使用
|
EP1893572B1
(en)
*
|
2004-06-18 |
2016-12-14 |
Millennium Pharmaceuticals, Inc. |
Factor xa inhibitors
|
US7696352B2
(en)
*
|
2004-06-18 |
2010-04-13 |
Millennium Pharmaceuticals, Inc. |
Factor Xa inhibitors
|
EP1768967B1
(en)
*
|
2004-07-20 |
2009-04-22 |
Symed Labs Limited |
Novel intermediates for linezolid and related compounds
|
TW200612923A
(en)
*
|
2004-07-29 |
2006-05-01 |
Ferrer Int |
Oxazolidinone compounds and compositions and methods related thereto
|
DE102004047840A1
(de)
*
|
2004-09-29 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004050283A1
(de)
*
|
2004-10-15 |
2006-04-27 |
Lanxess Deutschland Gmbh |
4-Aminophenyl-morpholinon-Derivate und deren Herstellung
|
US7662837B2
(en)
|
2004-10-22 |
2010-02-16 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
US7645755B2
(en)
|
2004-10-22 |
2010-01-12 |
Janssen Pharmaceutical N.V. |
Inhibitors of c-fms kinase
|
DE102004062475A1
(de)
*
|
2004-12-24 |
2006-07-06 |
Bayer Healthcare Ag |
Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
|
MX2007008434A
(es)
|
2005-01-19 |
2007-07-25 |
Squibb Bristol Myers Co |
Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
|
EP1685841A1
(en)
|
2005-01-31 |
2006-08-02 |
Bayer Health Care Aktiengesellschaft |
Prevention and treatment of thromboembolic disorders
|
US8221804B2
(en)
*
|
2005-02-03 |
2012-07-17 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
US7923041B2
(en)
|
2005-02-03 |
2011-04-12 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
DE102005018690A1
(de)
*
|
2005-04-22 |
2006-10-26 |
Bayer Healthcare Ag |
Imino-oxazolidine und ihre Verwendung
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
AU2006261828A1
(en)
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
WO2007002634A1
(en)
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
DE602006017694D1
(de)
|
2005-06-27 |
2010-12-02 |
Bristol Myers Squibb Co |
C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
|
EP1896417B1
(en)
|
2005-06-27 |
2011-03-23 |
Bristol-Myers Squibb Company |
Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
PE20070171A1
(es)
*
|
2005-06-30 |
2007-03-08 |
Boehringer Ingelheim Int |
GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
|
WO2007007588A1
(ja)
*
|
2005-07-08 |
2007-01-18 |
Ono Pharmaceutical Co., Ltd. |
平面性を有する環状基を母核とする化合物
|
US20070032473A1
(en)
*
|
2005-07-19 |
2007-02-08 |
Kai Gerlach |
Substituted amides and their use as medicaments
|
AR057976A1
(es)
*
|
2005-08-29 |
2008-01-09 |
Boehringer Ingelheim Int |
Biarilos sustituidos y su uso como medicamentos.
|
DE102005045518A1
(de)
|
2005-09-23 |
2007-03-29 |
Bayer Healthcare Ag |
2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
|
SG166126A1
(en)
*
|
2005-10-04 |
2010-11-29 |
Bayer Schering Pharma Ag |
Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
|
DE102005047561A1
(de)
|
2005-10-04 |
2007-04-05 |
Bayer Healthcare Ag |
Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
|
DE102005047558A1
(de)
*
|
2005-10-04 |
2008-02-07 |
Bayer Healthcare Ag |
Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
|
DE102005047564A1
(de)
|
2005-10-04 |
2007-05-31 |
Bayer Healthcare Ag |
Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
|
DE102005048824A1
(de)
*
|
2005-10-10 |
2007-04-12 |
Bayer Healthcare Ag |
Behandlung und Prophylaxe von Mikroangiopathien
|
NZ595182A
(en)
|
2005-10-18 |
2012-12-21 |
Janssen Pharmaceutica Nv |
Pharmaceutical uses of 4-cyano-1H-imidazole-2-carboxylic acid { 2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl} -amide
|
US7962847B2
(en)
*
|
2005-10-20 |
2011-06-14 |
International Business Machines Corporation |
Method for providing dynamic process step annotations
|
DE102005052174A1
(de)
*
|
2005-11-02 |
2007-06-06 |
Bayer Healthcare Ag |
Phenylen-bis-oxazolidin-Derivate und ihre Verwendung
|
JP2007154330A
(ja)
*
|
2005-12-01 |
2007-06-21 |
Nippon Paper Industries Co Ltd |
印刷用塗工紙
|
WO2007079186A2
(en)
*
|
2005-12-30 |
2007-07-12 |
Merck & Co., Inc. |
1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors
|
DE102006007146A1
(de)
|
2006-02-16 |
2007-08-23 |
Bayer Healthcare Ag |
Aminoacyl-Prodrugs
|
KR20080110877A
(ko)
|
2006-03-31 |
2008-12-19 |
재단법인 이쯔우 연구소 |
헤테로환을 갖는 신규 화합물
|
EP2015748B1
(en)
|
2006-04-20 |
2012-07-04 |
Janssen Pharmaceutica NV |
A C-Kit kinase inhibitor for use in the treatment of gastrointestinal stromal tumor or mastocytosis
|
ES2581600T3
(es)
|
2006-04-20 |
2016-09-06 |
Janssen Pharmaceutica, N.V. |
Inhibidores de quinasa c-fms
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
RU2475483C2
(ru)
|
2006-04-20 |
2013-02-20 |
Янссен Фармацевтика Н.В. |
Ингибиторы с-fms киназы
|
WO2007124316A1
(en)
|
2006-04-20 |
2007-11-01 |
Janssen Pharmaceutica N.V. |
Heterocyclic compounds as inhibitors of c-fms kinase
|
TW200813017A
(en)
*
|
2006-05-05 |
2008-03-16 |
Millennium Pharm Inc |
Factor XA inhibitors
|
DE102006025314A1
(de)
*
|
2006-05-31 |
2007-12-06 |
Bayer Healthcare Ag |
Arylsubstituierte Heterozyklen und ihre Verwendung
|
DE102006025319A1
(de)
*
|
2006-05-31 |
2007-12-06 |
Bayer Healthcare Aktiengesellschaft |
Substituierte Heterozyklen und ihre Verwendung
|
DE102006034916A1
(de)
*
|
2006-07-28 |
2008-01-31 |
Bayer Healthcare Ag |
Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten
|
DE102006039589A1
(de)
*
|
2006-08-24 |
2008-03-06 |
Bayer Healthcare Ag |
Aminoacyl-Prodrugs II
|
US7960569B2
(en)
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
DE102006051625A1
(de)
*
|
2006-11-02 |
2008-05-08 |
Bayer Materialscience Ag |
Kombinationstherapie substituierter Oxazolidinone
|
EP2102189B1
(en)
|
2006-12-15 |
2015-07-29 |
Bristol-Myers Squibb Company |
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
|
PE20081775A1
(es)
|
2006-12-20 |
2008-12-18 |
Bristol Myers Squibb Co |
Compuestos macrociclicos como inhibidores del factor viia
|
AU2008205093A1
(en)
*
|
2007-01-05 |
2008-07-17 |
Millennium Pharmaceuticals, Inc. |
Factor Xa inhibitors
|
EP2141154A4
(en)
*
|
2007-03-30 |
2011-06-01 |
Inst Med Molecular Design Inc |
OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11-HYDROXYSTEOID DEHYDROGENASE TYPE I
|
DE102007018662A1
(de)
*
|
2007-04-20 |
2008-10-23 |
Bayer Healthcare Ag |
Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie
|
KR20100015886A
(ko)
|
2007-04-23 |
2010-02-12 |
사노피-아벤티스 |
P2y12 길항제로서의 퀴놀린-카복스아미드 유도체
|
WO2008140220A1
(en)
*
|
2007-05-09 |
2008-11-20 |
Legochem Bioscience Ltd. |
Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
|
KR101009594B1
(ko)
|
2007-05-09 |
2011-01-20 |
주식회사 레고켐 바이오사이언스 |
P4 위치에 사이클릭 아미딘을 가지는 FXa 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물
|
DE102007028406A1
(de)
*
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028407A1
(de)
*
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028319A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028318A1
(de)
*
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Oxazolidinone zur Behandlung und Prophylaxe von Sepsis
|
DE102007028320A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007037373A1
(de)
|
2007-08-06 |
2009-02-19 |
Schebo Biotech Ag |
Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
|
WO2009018807A1
(de)
*
|
2007-08-06 |
2009-02-12 |
Schebo Biotech Ag |
Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie
|
US20090076264A1
(en)
*
|
2007-09-15 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched rivaroxaban
|
CN101883768A
(zh)
*
|
2007-10-02 |
2010-11-10 |
财团法人乙卯研究所 |
具有7元杂环的噁唑烷酮衍生物
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
EP2220079A2
(en)
|
2007-11-15 |
2010-08-25 |
Boehringer Ingelheim International GmbH |
Substituted amides, manufacturing and use thereof as medicaments
|
EP2229173A1
(en)
*
|
2007-12-11 |
2010-09-22 |
Bayer Schering Pharma Aktiengesellschaft |
Oxazolidinones for the treatment and/or prophylaxis of heart failure
|
WO2009080226A2
(en)
|
2007-12-26 |
2009-07-02 |
Sanofis-Aventis |
Heterocyclic pyrazole-carboxamides as p2y12 antagonists
|
WO2009132051A1
(en)
|
2008-04-21 |
2009-10-29 |
Signum Biosciences, Inc. |
Compounds, compositions and methods for making the same
|
DE102008028071A1
(de)
|
2008-06-12 |
2009-12-17 |
Bayer Schering Pharma Aktiengesellschaft |
Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure
|
EP2138178A1
(en)
*
|
2008-06-28 |
2009-12-30 |
Bayer Schering Pharma Aktiengesellschaft |
Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
|
KR100898361B1
(ko)
*
|
2008-07-03 |
2009-05-20 |
주식회사 레고켐 바이오사이언스 |
P4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 FXa 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
|
EP2140866A1
(en)
*
|
2008-07-04 |
2010-01-06 |
Bayer Schering Pharma Aktiengesellschaft |
Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
|
CA2729979A1
(en)
|
2008-07-08 |
2010-01-14 |
Ratiopharm Gmbh |
Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
|
KR101023174B1
(ko)
*
|
2008-09-24 |
2011-03-18 |
주식회사 레고켐 바이오사이언스 |
사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
|
US20100168111A1
(en)
*
|
2008-12-31 |
2010-07-01 |
Apotex Pharmachem Inc. |
Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
|
US20110288142A1
(en)
*
|
2009-01-30 |
2011-11-24 |
Chen Pingyun Y |
CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
|
US7816355B1
(en)
*
|
2009-04-28 |
2010-10-19 |
Apotex Pharmachem Inc |
Processes for the preparation of rivaroxaban and intermediates thereof
|
DK2442799T3
(da)
|
2009-06-18 |
2017-01-02 |
Krka Tovarna Zdravil D D Novo Mesto |
Fast farmaceutisk sammensætning omfattende rivaroxaban
|
EP2266541A1
(en)
|
2009-06-18 |
2010-12-29 |
Krka Tovarna Zdravil, D.D., Novo Mesto |
Solid pharmaceutical composition comprising rivaroxaban
|
KR101037051B1
(ko)
|
2009-07-08 |
2011-05-26 |
주식회사 레고켐 바이오사이언스 |
(s)-5-클로로-n-((3-(4-(5,6-다이하이드로-4h-1,2,4-옥사다이아진-3-일)페닐)-2-옥소옥사졸리딘-5-일)메틸)싸이오펜-2-카르복사미드 유도체의 제조방법
|
KR101037052B1
(ko)
*
|
2009-07-08 |
2011-05-26 |
주식회사 레고켐 바이오사이언스 |
5-클로로-n-(((5s)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4h)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체
|
ES2905760T3
(es)
*
|
2009-07-31 |
2022-04-12 |
Krka D D Novo Mesto |
Procedimientos para la cristalización del rivaroxabán
|
WO2011042156A1
(en)
|
2009-10-06 |
2011-04-14 |
Ratiopharm Gmbh |
Pharmaceutical compositions comprising rivaroxaban
|
EP2308472A1
(en)
|
2009-10-06 |
2011-04-13 |
ratiopharm GmbH |
Pharmaceutical compositions comprising rivaroxaban
|
WO2011061760A1
(en)
*
|
2009-11-18 |
2011-05-26 |
Cadila Healthcare Limited |
Novel antithrombotic agents
|
US8742120B2
(en)
*
|
2009-12-17 |
2014-06-03 |
Millennium Pharmaceuticals, Inc. |
Methods of preparing factor xa inhibitors and salts thereof
|
EP2513094B1
(en)
|
2009-12-17 |
2015-12-16 |
Millennium Pharmaceuticals, Inc. |
Crystalline salts of a factor xa inhibitor
|
CN102822167A
(zh)
*
|
2010-01-04 |
2012-12-12 |
埃南蒂亚有限公司 |
用于制备利伐沙班的方法及其中间体
|
EP2354128A1
(en)
*
|
2010-02-10 |
2011-08-10 |
Sandoz Ag |
Method for the preparation of rivaroxaban
|
TWI577665B
(zh)
|
2010-02-11 |
2017-04-11 |
必治妥美雅史谷比公司 |
作為因子xia抑制劑之巨環類
|
EA015918B1
(ru)
|
2010-03-03 |
2011-12-30 |
Дмитрий Геннадьевич ТОВБИН |
УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
|
DE102010018299A1
(de)
|
2010-04-23 |
2011-10-27 |
Archimica Gmbh |
Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
|
DE102010028362A1
(de)
|
2010-04-29 |
2011-11-03 |
Bayer Schering Pharma Aktiengesellschaft |
Herstellverfahren
|
KR101799429B1
(ko)
*
|
2010-05-03 |
2017-11-21 |
에스케이바이오팜 주식회사 |
신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
|
EP2388260A1
(de)
|
2010-05-21 |
2011-11-23 |
Archimica GmbH |
Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
|
CN107021932A
(zh)
*
|
2010-06-29 |
2017-08-08 |
欧美嘉股份有限公司 |
制备5‑左旋‑氨甲基‑3‑芳基‑2‑恶唑烷酮类的方法
|
EP2404920A1
(en)
|
2010-07-06 |
2012-01-11 |
Sandoz AG |
Crystalline form of Rivaroxaban dihydrate
|
US20130253187A1
(en)
|
2010-09-14 |
2013-09-26 |
Medichem, S.A. |
Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
|
CZ2010714A3
(cs)
|
2010-09-30 |
2012-04-11 |
Farmak, A. S. |
Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote
|
CA2815063C
(en)
|
2010-10-18 |
2016-11-22 |
Apotex Pharmachem Inc. |
Processes for the preparation of rivaroxaban and intermediates thereof
|
CN102464658B
(zh)
*
|
2010-11-03 |
2014-04-16 |
天津药物研究院 |
噁唑烷酮衍生物及其制备方法和用途
|
DE102010063127A1
(de)
|
2010-12-15 |
2012-06-21 |
Bayer Schering Pharma Aktiengesellschaft |
Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
|
CA2824885A1
(en)
|
2011-01-19 |
2012-07-26 |
Bayer Intellectual Property Gmbh |
Binding proteins to inhibitors of coagulation factors
|
CN102199150A
(zh)
*
|
2011-04-01 |
2011-09-28 |
中国药科大学 |
光学活性噁唑烷酮类衍生物及其制备方法与在制药中的用途
|
EP2697209B1
(en)
|
2011-04-11 |
2015-09-23 |
Sandoz AG |
Method for the preparation of substituted oxazolidinones
|
US9556163B2
(en)
|
2011-05-06 |
2017-01-31 |
Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag |
Process for the preparation of a rivaroxaban and intermediates formed in said process
|
WO2012156983A1
(en)
*
|
2011-05-16 |
2012-11-22 |
Symed Labs Limited |
Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
|
ES2395304B1
(es)
*
|
2011-05-20 |
2014-01-16 |
Interquim, S.A. |
Procedimiento de obtención de una tiofen-2-carboxamida.
|
CN102796092B
(zh)
*
|
2011-05-24 |
2015-04-08 |
北大方正集团有限公司 |
噁唑烷酮衍生物及其制备方法和应用
|
CN102796091A
(zh)
*
|
2011-05-24 |
2012-11-28 |
北大方正集团有限公司 |
取代的噁唑烷酮化合物及其制备方法和应用
|
CN102320988B
(zh)
*
|
2011-06-03 |
2014-04-09 |
中国科学院上海有机化学研究所 |
4-(4-氨基苯基)-3-吗啉酮中间体酰胺、合成方法和用途
|
CN102827154B
(zh)
*
|
2011-06-14 |
2015-04-22 |
上海科胜药物研发有限公司 |
一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
|
TW201319068A
(zh)
|
2011-08-05 |
2013-05-16 |
必治妥美雅史谷比公司 |
作為xia因子抑制劑之環狀p1接合劑
|
TW201311689A
(zh)
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子xia抑制劑之新穎巨環化合物
|
EP2753619A2
(en)
|
2011-09-08 |
2014-07-16 |
Cadila Healthcare Limited |
Processes and intermediates for preparing rivaroxaban
|
EP2573084A1
(en)
|
2011-09-22 |
2013-03-27 |
Enantia, S.L. |
Novel crystalline forms of rivaroxaban and processes for their preparation
|
WO2013046211A1
(en)
*
|
2011-09-27 |
2013-04-04 |
Symed Labs Limited |
Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof
|
WO2013053739A1
(en)
|
2011-10-10 |
2013-04-18 |
Laboratorios Lesvi, S. L. |
Process for preparing factor xa inhibitors
|
HU230734B1
(hu)
|
2011-10-10 |
2017-12-28 |
EGIS Gyógyszergyár Nyrt |
Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok
|
US9233989B2
(en)
*
|
2011-10-11 |
2016-01-12 |
Council Of Scientific & Industrial Research |
Sila analogs of oxazolidinone derivatives and synthesis thereof
|
PL2766346T3
(pl)
|
2011-10-14 |
2017-09-29 |
Bristol-Myers Squibb Company |
Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA
|
CN103987696B
(zh)
|
2011-10-14 |
2016-12-21 |
百时美施贵宝公司 |
作为因子xia抑制剂的取代的四氢异喹啉化合物
|
ES2699226T3
(es)
|
2011-10-14 |
2019-02-08 |
Bristol Myers Squibb Co |
Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
|
CN102408420B
(zh)
*
|
2011-10-19 |
2014-10-22 |
汕头经济特区鮀滨制药厂 |
一种利伐沙班及其中间体的制备方法以及中间体化合物
|
EP2812329A2
(en)
|
2012-02-06 |
2014-12-17 |
Megafine Pharma (P) Ltd. |
A process for preparation of rivaroxaban and intermediates thereof
|
CZ2012111A3
(cs)
|
2012-02-16 |
2013-08-28 |
Zentiva, K.S. |
Zpusob prípravy rivaroxabanu zalozený na vyuzití (S)-epichlorhydrinu
|
CZ2012114A3
(cs)
|
2012-02-17 |
2013-02-20 |
Zentiva, K.S. |
Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
|
CN103288814B
(zh)
|
2012-02-24 |
2016-07-06 |
国药集团国瑞药业有限公司 |
一种利伐沙班中间体的制备方法
|
WO2013151719A2
(en)
*
|
2012-04-05 |
2013-10-10 |
Scifluor Life Sciences, Llc |
Fluorinated oxazolidinone derivatives
|
US9562040B2
(en)
|
2012-04-06 |
2017-02-07 |
Indiana University Research And Technology Corporation |
Processes for preparing Rivaroxaban
|
AU2013250801A1
(en)
|
2012-04-16 |
2014-11-06 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of rivaroxaban and intermediates thereof
|
CA2871339C
(en)
*
|
2012-05-02 |
2016-08-23 |
Symed Labs Limited |
Improved process for preparing rivaroxaban
|
EP2855465A1
(en)
*
|
2012-05-24 |
2015-04-08 |
Ranbaxy Laboratories Limited |
Process for the preparation of rivaroxaban
|
CN102746287B
(zh)
*
|
2012-06-21 |
2014-05-28 |
成都苑东药业有限公司 |
一种恶唑烷酮化合物及其制备方法
|
UY34856A
(es)
|
2012-07-03 |
2013-12-31 |
Bayer Pharma AG |
Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
|
CN102757424B
(zh)
*
|
2012-07-09 |
2014-10-15 |
云南大学 |
2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法
|
CN102746288B
(zh)
*
|
2012-07-24 |
2015-04-08 |
常州制药厂有限公司 |
一种抗凝血药及其关键中间体的制备方法
|
CN108250199B
(zh)
|
2012-08-03 |
2021-07-16 |
百时美施贵宝公司 |
二氢吡啶酮p1作为凝血因子xia抑制剂
|
UY34959A
(es)
|
2012-08-03 |
2014-01-31 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Dihidropiridona p1 como inhibidores del factor xia
|
IN2015DN00659A
(US07585860-20090908-C00162.png)
|
2012-08-07 |
2015-06-26 |
Janssen Pharmaceutica Nv |
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
CN103626749A
(zh)
*
|
2012-08-21 |
2014-03-12 |
苏州泽璟生物制药有限公司 |
取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
|
WO2014049552A2
(en)
|
2012-09-26 |
2014-04-03 |
Ranbaxy Laboratories Limited |
Process for the preparation of rivaroxaban
|
CN103864773B
(zh)
*
|
2012-12-13 |
2017-03-15 |
北京藏卫信康医药研发有限公司 |
利伐沙班及其中间体的制备方法
|
ES2647607T3
(es)
|
2012-12-21 |
2017-12-22 |
Farma Grs, D.O.O. |
Procedimiento para la preparación de rivaroxabán
|
PL2895176T3
(pl)
|
2012-12-26 |
2017-05-31 |
Wanbury Limited |
Związek pośredni Rywaroksabanu i jego wytwarzanie
|
CN105431429A
(zh)
*
|
2012-12-26 |
2016-03-23 |
Wanbury有限公司 |
取代的噁唑烷酮类的醛衍生物
|
US9663505B2
(en)
|
2013-03-25 |
2017-05-30 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of rivaroxaban
|
EP2978751B1
(en)
|
2013-03-25 |
2018-12-05 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
|
CN104098556B
(zh)
*
|
2013-04-09 |
2019-01-08 |
浙江九洲药物科技有限公司 |
一种利伐沙班的合成工艺
|
CN103242307B
(zh)
*
|
2013-05-17 |
2015-08-12 |
天津药物研究院有限公司 |
一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
|
CN104163819A
(zh)
*
|
2013-05-17 |
2014-11-26 |
天津药物研究院 |
一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
|
WO2014195230A1
(de)
|
2013-06-03 |
2014-12-11 |
Bayer Pharma Aktiengesellschaft |
Substituierte benzoxazole
|
US20160108039A1
(en)
*
|
2013-06-03 |
2016-04-21 |
Bayer Pharma Aktiengesellschaft |
Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases
|
UY35592A
(es)
|
2013-06-03 |
2014-12-31 |
Bayer Pharma AG |
Benzoxazoles sustituidos
|
WO2015011617A1
(en)
|
2013-07-23 |
2015-01-29 |
Ranbaxy Laboratories Limited |
Process for the preparation of rivaroxaban
|
US9598403B2
(en)
|
2013-08-19 |
2017-03-21 |
Amneal Pharmaceuticals Llc |
Process for the preparation of rivaroxaban
|
WO2015104605A1
(en)
|
2014-01-08 |
2015-07-16 |
Wockhardt Limited |
A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
|
WO2015111076A2
(en)
*
|
2014-01-23 |
2015-07-30 |
Symed Labs Limited |
Improved processes for the preparation of highly pure rivaroxaban crystal modification i
|
NO2760821T3
(US07585860-20090908-C00162.png)
|
2014-01-31 |
2018-03-10 |
|
|
HUE040226T2
(hu)
|
2014-01-31 |
2019-02-28 |
Bristol Myers Squibb Co |
Makrociklusok heterociklusos P2' csoportokkal XIA faktor inhibitorokként
|
WO2015124995A1
(en)
|
2014-02-19 |
2015-08-27 |
Aurobindo Pharma Ltd |
Solid dosage forms of rivaroxaban
|
WO2015155307A1
(en)
|
2014-04-11 |
2015-10-15 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
|
CN104974149B
(zh)
*
|
2014-04-14 |
2018-05-01 |
北大方正集团有限公司 |
一种利伐沙班的制备方法
|
CN105085371B
(zh)
*
|
2014-04-22 |
2017-06-16 |
北大方正集团有限公司 |
(s)‑{1‑(氯甲酸酯基)‑2‑[2‑(1,3‑二氧异吲哚)基]乙基}卤化盐及其制备方法
|
KR101499867B1
(ko)
*
|
2014-04-22 |
2015-03-06 |
에스케이케미칼주식회사 |
활성 성분 (i) 함유 조성물 및 이의 제조 방법
|
CN105085370B
(zh)
*
|
2014-04-22 |
2017-04-12 |
北大方正集团有限公司 |
(s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
|
EP2942058A1
(en)
|
2014-05-09 |
2015-11-11 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Pharmaceutical combinations of rivaroxaban and H2-receptor antagonists
|
CN104031036A
(zh)
*
|
2014-05-16 |
2014-09-10 |
南通常佑药业科技有限公司 |
一种利伐沙班的制备方法
|
JP2017516845A
(ja)
|
2014-05-22 |
2017-06-22 |
ノース チャイナ ファーマシューティカル カンパニー リミテッド |
血液凝固因子Xa阻害剤としてのヒドラジド化合物
|
CN103980221B
(zh)
*
|
2014-05-26 |
2016-03-23 |
山东康美乐医药科技有限公司 |
4-(硝基苯基)-3-吗啉酮的制备方法及利用其制备利伐沙班的方法
|
DE102014108210A1
(de)
|
2014-06-11 |
2015-12-17 |
Dietrich Gulba |
Rodentizid
|
WO2015198259A1
(en)
|
2014-06-26 |
2015-12-30 |
Erregierre S.P.A. |
Process for the synthesis of rivaroxaban and intermediate for the production thereof
|
TW201607923A
(zh)
|
2014-07-15 |
2016-03-01 |
歌林達有限公司 |
被取代之氮螺環(4.5)癸烷衍生物
|
WO2016008582A1
(en)
|
2014-07-15 |
2016-01-21 |
Grünenthal GmbH |
Substituted azaspiro(4.5)decane derivatives
|
CN104086539A
(zh)
*
|
2014-07-17 |
2014-10-08 |
天津炜捷制药有限公司 |
一种利伐沙班的制备方法
|
EP3186246A1
(en)
|
2014-08-25 |
2017-07-05 |
Cipla Limited |
Process for the preparation of rivaroxaban
|
NO2721243T3
(US07585860-20090908-C00162.png)
|
2014-10-01 |
2018-10-20 |
|
|
CN104356124A
(zh)
*
|
2014-10-30 |
2015-02-18 |
广东东阳光药业有限公司 |
噁唑烷酮类化合物及其组合物和用途
|
CN104402876A
(zh)
*
|
2014-11-25 |
2015-03-11 |
沈阳药科大学 |
噁唑烷酮类化合物及其应用
|
CN104478869B
(zh)
*
|
2014-12-05 |
2017-04-12 |
广东东阳光药业有限公司 |
噁唑烷酮类化合物及其在药物中的应用
|
CN104447729A
(zh)
*
|
2014-12-05 |
2015-03-25 |
广东东阳光药业有限公司 |
噁唑烷酮类化合物及其在药物中的应用
|
CN104478866B
(zh)
*
|
2014-12-05 |
2017-07-07 |
广东东阳光药业有限公司 |
噁唑烷酮类化合物及其在药物中的应用
|
CN104447728B
(zh)
*
|
2014-12-05 |
2017-01-04 |
广东东阳光药业有限公司 |
噁唑烷酮类化合物及其在药物中的应用
|
CN104497008B
(zh)
*
|
2014-12-09 |
2016-11-16 |
广东东阳光药业有限公司 |
取代噁唑烷酮类化合物及其使用方法和用途
|
CN104496978A
(zh)
*
|
2014-12-09 |
2015-04-08 |
广东东阳光药业有限公司 |
取代噁唑烷酮类化合物及其使用方法和用途
|
CN104530029B
(zh)
*
|
2014-12-09 |
2017-04-12 |
广东东阳光药业有限公司 |
作为Xa因子抑制剂的杂环化合物及其使用方法和用途
|
CN104530030A
(zh)
*
|
2014-12-10 |
2015-04-22 |
广东东阳光药业有限公司 |
噁唑烷酮类化合物及其在药物中的应用
|
CN104530080B
(zh)
*
|
2014-12-10 |
2017-01-11 |
广东东阳光药业有限公司 |
噁唑烷酮类化合物及其在药物中的应用
|
CN104530031A
(zh)
*
|
2014-12-10 |
2015-04-22 |
广东东阳光药业有限公司 |
噁唑烷酮类化合物及其在药物中的应用
|
CN105777734A
(zh)
*
|
2014-12-22 |
2016-07-20 |
常州方楠医药技术有限公司 |
一种利伐沙班中间体的合成方法
|
CN104557900A
(zh)
*
|
2014-12-23 |
2015-04-29 |
中国药科大学 |
噁唑烷酮类化合物及其制备方法与医药用途
|
CN105820161A
(zh)
*
|
2015-01-08 |
2016-08-03 |
常州方楠医药技术有限公司 |
一种利伐沙班中间体5-羟基甲基噁唑烷酮衍生物的合成方法
|
TR201501970A2
(en)
|
2015-02-19 |
2016-09-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical combinations of dronedarone.
|
CN107406440B
(zh)
*
|
2015-03-20 |
2021-05-07 |
豪夫迈·罗氏有限公司 |
Bace1抑制剂
|
WO2016150937A1
(en)
|
2015-03-25 |
2016-09-29 |
Lonza Ltd |
Method for preparation of thiophenecarbonyl chlorides
|
CN104926807B
(zh)
*
|
2015-06-04 |
2017-10-31 |
沈阳药科大学 |
一种利伐沙班相关物质“二胺”及其合成方法
|
EP3310777B1
(en)
|
2015-06-19 |
2019-10-09 |
Bristol-Myers Squibb Company |
Diamide macrocycles as factor xia inhibitors
|
ES2937156T3
(es)
|
2015-07-29 |
2023-03-24 |
Bristol Myers Squibb Co |
Inhibidores macrocíclicos del factor XIa que llevan un grupo P2' no aromático
|
JP6785838B2
(ja)
|
2015-08-05 |
2020-11-18 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
新規な置換グリシン誘導のfxia阻害剤
|
CN108290877A
(zh)
|
2015-11-04 |
2018-07-17 |
隆萨有限公司 |
用草酰氯制备噻吩-2-甲酰氯的方法
|
SI3377176T1
(sl)
|
2016-02-23 |
2022-03-31 |
Morgandane Scientific, LLC |
Postopek zdravljenja pacientov s sočasnim dajanjem rivaroksabana in verapamila
|
EP3423458A1
(en)
|
2016-03-02 |
2019-01-09 |
Bristol-Myers Squibb Company |
Diamide macrocycles having factor xia inhibiting activity
|
WO2018001914A1
(en)
|
2016-06-28 |
2018-01-04 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical capsule composition of rivaroxaban
|
CN106588905A
(zh)
*
|
2016-12-13 |
2017-04-26 |
重庆英斯凯化工有限公司 |
一种利伐沙班中间体的制备方法
|
US11034683B2
(en)
|
2017-01-04 |
2021-06-15 |
Unichem Laboratories Ltd |
Process for the preparation of rivaroxaban involving novel intermediate
|
CN107586291B
(zh)
*
|
2017-11-03 |
2019-08-20 |
梯尔希(南京)药物研发有限公司 |
一种利伐沙班代谢物5的合成方法
|
CN107857739A
(zh)
*
|
2017-11-14 |
2018-03-30 |
安徽华胜医药科技有限公司 |
一种氘代利伐沙班关键中间体及其制备方法
|
CN107857761A
(zh)
*
|
2017-11-14 |
2018-03-30 |
安徽华胜医药科技有限公司 |
一种氘代利伐沙班及其制备方法
|
CN108164519A
(zh)
*
|
2017-12-28 |
2018-06-15 |
江苏悦兴医药技术有限公司 |
利伐沙班工艺杂质的合成方法
|
EP3505160A1
(en)
|
2017-12-31 |
2019-07-03 |
Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. |
Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof
|
HU231119B1
(hu)
|
2018-01-12 |
2020-11-30 |
Richter Gedeon Nyrt. |
Eljárás 4-(4-aminofenil)morfolin-3-on előállítására
|
US10828310B2
(en)
|
2018-02-02 |
2020-11-10 |
Bayer Pharma Aktiengesellschaft |
Reducing the risk of cardiovascular events
|
GB201807014D0
(en)
|
2018-04-30 |
2018-06-13 |
Univ Leeds Innovations Ltd |
Factor xlla inhibitors
|
CN108546265A
(zh)
*
|
2018-06-22 |
2018-09-18 |
苏州中联化学制药有限公司 |
一种利伐沙班中间体的合成方法
|
US10722486B2
(en)
|
2018-08-13 |
2020-07-28 |
Morgandane Scientific, LLC |
Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
|
CN110054621A
(zh)
*
|
2019-03-12 |
2019-07-26 |
浙江天宇药业股份有限公司 |
一种利伐沙班中间体的制备方法
|
CN110615756A
(zh)
*
|
2019-06-28 |
2019-12-27 |
南京红杉生物科技有限公司 |
1-(4-硝基苯基)哌啶-2-酮及其合成方法和应用
|
US11608320B2
(en)
|
2020-02-02 |
2023-03-21 |
Kuwait University |
Oxazolidinone hydroxamic acid derivatives
|
CN111253383A
(zh)
*
|
2020-03-27 |
2020-06-09 |
南京国星生物技术研究院有限公司 |
一种利伐沙班的合成方法
|
CN112159402B
(zh)
*
|
2020-10-28 |
2022-04-05 |
南京法恩化学有限公司 |
一种利伐沙班的制备方法
|
GB202102575D0
(en)
|
2021-02-23 |
2021-04-07 |
Teva Pharmaceutical Industries Ltd |
Fixed-dose pharmaceutical compositions
|
EP4070658A1
(de)
|
2021-04-06 |
2022-10-12 |
BIORoxx GmbH |
Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
|
GB202107722D0
(en)
|
2021-05-28 |
2021-07-14 |
Lunac Therapeutics Ltd |
Factor XIIA Inhibitors
|
CN115260117B
(zh)
*
|
2022-08-09 |
2024-05-28 |
江苏法安德医药科技有限公司 |
一种4-(4-氨基苯基)吗啡啉-3-酮的合成方法
|